HC Wainwright Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price lifted by analysts at HC Wainwright from $82.00 to $95.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 82.06% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group lifted their price objective on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Barclays dropped their price objective on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Canaccord Genuity Group restated a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Wedbush increased their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, October 22nd. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $85.92.

Ultragenyx Pharmaceutical Stock Up 2.2 %

NASDAQ RARE opened at $52.18 on Wednesday. The firm has a 50 day moving average of $55.47 and a two-hundred day moving average of $48.09. The stock has a market capitalization of $4.81 billion, a PE ratio of -7.15 and a beta of 0.58. Ultragenyx Pharmaceutical has a 52 week low of $34.06 and a 52 week high of $60.37.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,556 shares of company stock worth $1,515,967. 5.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 8.8% during the third quarter. Victory Capital Management Inc. now owns 10,948 shares of the biopharmaceutical company’s stock worth $608,000 after purchasing an additional 884 shares during the period. Atria Investments Inc purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $269,000. Capital Performance Advisors LLP acquired a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $107,000. Principal Financial Group Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 740.0% during the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock worth $4,802,000 after acquiring an additional 76,150 shares in the last quarter. Finally, Emerald Advisers LLC boosted its position in Ultragenyx Pharmaceutical by 17.1% during the third quarter. Emerald Advisers LLC now owns 569,798 shares of the biopharmaceutical company’s stock valued at $31,652,000 after purchasing an additional 83,116 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.